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Abstract The two-micron (thulium) laser is the newest laser
technique for treatment of bladder outlet obstruction resulting
from benign prostatic hyperplasia (BPH). It takes less operative
time than standard techniques, provides clear vision and lower
blood loss as well as shorter catheterization times and hospital-
ization times. It has been identified to be a safe and efficient
method for BPH treatment regardless of the prostate size.
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Introduction
Benign prostatic hyperplasia (BPH) is a common disease in
aged men. Transurethral resection of the prostate (TURP) is
considered the gold standard in the treatment of patients with
BPH. However, because of the relatively high rate of compli-
cations associated with TURP, various alternative laser treat-
ment options have more recently been developed. Laser pros-
tatectomy has increasingly replaced TURP over the past
10 years in the world [1•]. Thulium laser performs excellent
haemostasis and coagulation, presents effective resection and
vaporization of prostate tissue [2, 3••, 4, 5].
Thulium Laser
The thulium laser is a continuous wave laser that possesses a
wavelength similar to holmium laser. It emits a wavelength of
2013 nm, close to the peak absorption of water [6, 7]. The
continuous wave pattern helps to produce fast, hemostatic cuts
during the prostatectomy. Due to the relatively well-preserved
hemostasis, thulium laser prostatectomy reduces blood loss
and provides relatively clear vision during an operation. The
procedure is performed using a Tm:YAG laser (Revolix, LISA
laser products, Katlenburg, Germany) with a laser power level
between 50 to 120 W. Laser energy is typically delivered via
an end-firing reusable 550 μm laser fiber [2].
Thulium Laser Prostatectomy
Fried and Murray first reported thulium laser vaporization of
canine prostates in 2005 [8]. Several techniques for thulium
laser prostatectomy have been demonstrated like ablation,
resection and enucleation. There are two significant advan-
tages of using the thulium laser. First, it can operate in
continuous-wave mode, so that coagulation and therefore
hemostasis are optimized. Secondly, the wavelength of the
thulium laser is close to the peak of the absorption spectrum of
water, leading to a more pronounced resection and vaporiza-
tion effect in prostate tissue [2, 3••, 4, 5].
Fried was the first to report that the thulium laser could
cause rapid vaporization and coagulation of the prostate [8].
The thulium laser vapo-enucleation (ThuLEP) and thulium
laser resection of the prostate tangerine technique (TmLRP-
TT) techniques were introduced by Bach et al. [6] and Xia
et al. [9] respectively. Both studies demonstrated excellent
hemostasis while showing improvements in urinary flow rate
(Qmax), postvoid residual (PVR), International Prostate
Symptom Score (IPSS) and Quality of Life Index (QoL).
TmLRP-TTwas superior to TURP in terms of drop in hemo-
globin (0.92+/-0.82 g/dl vs. 1.46+/-0.65 g/dl, p<0.001). More
recently, Zhang et al. [10•] compared ThuLEP to holmium
laser enucleation of the prostate (HoLEP) in 131 patients,
Q. Jiang : S. Xia (*)
Department of Urology, Shanghai First People’s Hospital,
School of Medicine, Shanghai Jiao Tong University,
No.100, Haining Road, Shanghai 200080, China
e-mail: xsjurologist@163.com
Curr Bladder Dysfunct Rep (2014) 9:142–144
DOI 10.1007/s11884-014-0233-z
where blood loss was found to be lower in the former vs. the
latter technology (130.0 vs. 166.6 mL, P=0.045). Additional-
ly, Wendt-Nordahl et al. found that the thulium laser offered a
higher tissue ablation capacity compared to KTP laser with a
reduced bleeding rate compared to TURP [11]. In this study,
70 W thulium laser displays a higher tissue ablation rate,
reaching 6.56+/-0.69 g after 10 minutes, compared to the
80 W KTP laser (3.99+/-0.48 g; P<0.05), and offers a signif-
icantly reduced bleeding rate (0.16+/-0.07 g/min) compared to
TURP (20.14+/-2.03 g/min; P<0.05). Recently, in a prospec-
tive study of 1080 patients undergoing ThuVEP, Gross et al.
showed that median maximum urinary flow rate (8.9 vs
18.4 ml/s) and postvoid residual urine volume (120 vs
20 ml) changed significantly (p<0.001), and the overall com-
plication rates decreased significantly over time [12••].
The TmLRP-TT technique can be used to dissect entire
prostatic lobes off the surgical capsule, similar to peeling a
tangerine [9]. The tissue is then resected into small tissue chips
before falling off into the bladder. The glandular chips are
small, and can be flushed out through the sheath of the
resectoscope directly without need for a tissue morcellator.
Compared with TURP, TmLRP-TT had decreased catheteri-
zation time (45.6 versus 87.4 hours), decreased hospital stay
(115.1 versus 161.1 hours), and caused less of a drop in
hemoglobin (0.92 versus 1.46 g/dL) [13]. The hemostasis of
thulium laser also appears superior to HoLEP (EBL of 130.0
vs 166.6 mL, p=0.045) [10•]. From a 4-year follow-up,
TmLRP-TT maintains stable micturition, lower peri-
operative morbidity, and equally low incidence of late adverse
effects [14•]. IPSS and QoL decreased 61.2 % and 59.1 %
respectively at the end of the follow-up. Qmax increased
107 % and PVR decreased 73.1 %. Bach et al. [15] performed
thulium laser vapo-enucleation (ThuLEP) in 88 patients. In
these patients, Foley catheter-time was 2.1±1.06 days on
average, and early complications were minimal with 27 % of
patients experiencing short-term dysuria. By comparing 70W
with 120 W [16], Netsch et al. found that 120 Wenhances the
effectiveness of ThuLEP with regard to the percentage of
resected tissue and the enucleation/operation efficiency.
Attempting transurethral resection for prostates with large
volumes may prolong operation time and result in an in-
creased learning curve compared to resection of smaller pros-
tates. Wei et al. [17•] compared the safety and efficiency of
TmLRP-TT vs. plasmakinetic resection of the prostate
(PKRP) for BPH patients with large volume prostates
(>80 ml) with an 18-month follow-up. Although there was
no statistical difference in operative time (103.00 vs. 99.58mi-
nutes, p=0.54), the TmLRP-TT group experienced a smaller
decline in hemoglobin (0.86±0.42 vs. 1.34±1.04 g/dl, p<
0.01), shorter catheterization time (1.91±0.85 vs. 2.36±
0.74 days, p<0.01) and hospitalization time (3.80±0.46 vs.
5.02±0.54 days, p<0.01) compared to the PKRP group. Yang
et al. reported that ThuLEP resulted in less hemoglobin
decrease (0.15 vs 0.30 g/dL, p=0.045), shorter catheterization
time (2.1 vs 3.5 days, p=0.031), less irrigation volume (12.4
vs 27.2 L, p=0.022), and shorter hospital stay (2.5 vs 4.6 days,
p=0.026) compared to PRKP but equivalency in Qmax, IPSS,
PVR, and QOLS [18•]. In another study by Bach [3••], it was
reported that prostates larger than 80 mL could be safely
treated with a manageable risk of complications by ThuLEP.
In a series of 90 patients, only two patients required blood
transfusion, while ten experienced early postoperative stress
incontinence. 7 % of patients experienced symptomatic uri-
nary tract infection. Prostate volume was reduced 86 % on
transrectal ultrasound, while peak urinary flow rate, Interna-
tional Prostate Symptom Score, and quality of life all were
improved significantly (p <0.001).
Recently, Netsch et al. [19••] evaluated the safety and
efficacy of ThuVEP for patients on systemic anticoagulation.
Acute postoperative bleeding was seen in four patients, while
7.1 % patients showed delayed bleeding; 7.1 % of patients
required transfusion. Median QoL, IPSS, Qmax, and
postvoiding residual urine all improved significantly. It ap-
pears that thulium laser is a safe and efficacy treatment for
BPH patients on systemic anticoagulation.
In a meta-analysis from Tang et al. [21••], nine trials were
examined to assess the performance of TmLRP vs. TURP.
Patients undergoing TmLRP experienced smaller declines in
serum sodium levels (p<0.001), hemoglobin levels (p<
0.001), shorter durations of catheterization (p<0.001), shorter
lengths of hospital stay (p<0.001), and fewer total complica-
tions (p<0.001). Thulium laser prostatectomy appeared to be
a safe, feasible, and efficient alternative to TURP with inter-
estingly a relative short learning curve of 8 to 16 cases
reported by Netsch et al. [20•].
Conclusions
Thulium laser prostatectomy represents a safe and efficacious
procedure for BPH, with higher tissue ablation capacity and
improved hemostasis. Thulium laser can be a better option for
BPH patients, particularly for high-risk procedures or proce-
dures involving large prostates.
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